Cassiopea S.p.A., IT0005108359

Cassiopea S.p.A., IT0005108359

03.11.2021 - 07:05:06

EQS-News: Cassiopea SpA announces the US launch of Winlevi

About Cassiopea Cassiopea is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The Company's strategy is to leverage this expertise to optimize the commercial potential for its products directly or with a partner. For further information on Cassiopea, please visit

About Winlevi(R)

Winlevi(R) (clascoterone cream 1%) is approved for the topical treatment of acne vulgaris in people aged 12 and older. Although the exact mechanism of action for Winlevi(R) is unknown, laboratory studies suggest the active ingredient, clascoterone, competes with androgens, specifically dihydrotestosterone (DHT), for binding to the androgen receptors within the sebaceous gland and hair follicles.4 Complete prescribing information is available at

Indication Winlevi (clascoterone cream 1%) is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

Important Safety Information


WARNINGS AND PRECAUTIONS Local Irritation: Pruritus, burning, skin redness or peeling may be experienced with WINLEVI(R) cream. If these effects occur, discontinue or reduce the frequency of application of WINLEVI(R) cream.

Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur during or after treatment with WINLEVI(R). In the PK trial, HPA axis suppression was observed in 1/20 (5%) of adult subjects and 2/22 (9%) of adolescent subjects at Day 14. All subjects returned to normal HPA axis function at follow-up 4 weeks after stopping treatment. Conditions which augment systemic absorption include use over large surface areas, prolonged use, and the use of occlusive dressings. Attempt to withdraw use if HPA axis suppression develops.

Pediatric patients may be more susceptible to systemic toxicity.

Hyperkalemia: Elevated potassium levels were observed in some subjects during the clinical trials. Shifts from normal to elevated potassium levels were observed in 5% of WINLEVI(R)-treated subjects and 4% of vehicle-treated subjects.

ADVERSE REACTIONS Most common adverse reactions occurring in 7 to 12% of patients are erythema/reddening, pruritus and scaling/dryness. Additionally, edema, stinging, and burning occurred in >3% of patients and were reported in a similar percentage of subjects treated with vehicle.


WINLEVI(R). Package Insert. Cassiopea. 2020. US FDA. Novel Drug Approvals for 2020. Accessed March 15, 2021. The American Academy of Dermatology. Skin conditions by the numbers. American Academy of Dermatology. Accessed March 15, 2021. Rosette C, et al. J Drugs Dermatol. 2019; 18(5):412-418.

Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Neither Cassiopea has any obligation to publicly update or revise any forward-looking statements.


Cassiopea SpA

Diana Harbort, CEO & Head of Investor Relations Tel ???????????????? +39 02 868 911 24 E-mail????????????

End of Media Release

Language: English Company: Cassiopea S.p.A. Via Cristoforo Colombo 1 20045 Lainate

Switzerland E-mail: Internet: ISIN: IT0005108359 Listed: SIX Swiss Exchange EQS News ID: 1245662 ? End of News EQS Group News Service